Document 0872
 DOCN  M9550872
 TI    The need for additional options in the treatment of human
       immunodeficiency virus infection.
 DT    9505
 AU    Volberding P; San Francisco General Hospital, AIDS Program, University
       of; California 94110.
 SO    J Infect Dis. 1995 Mar;171 Suppl 2:S150-4. Unique Identifier : AIDSLINE
       MED/95164991
 AB    Current therapy for human immunodeficiency virus (HIV) infection is
       inadequate to control the progression of the disease. Although existing
       nucleoside analogues, such as zidovudine, have clear benefits, they also
       have drawbacks, including toxicity and the possibility of drug
       resistance. In addition, the timing of therapy and the use of
       monotherapy versus combination therapy as initial treatment have not
       been definitively established. HIV drugs currently in development
       include newer nucleoside analogues, such as stavudine and lamivudine,
       nonnucleoside reverse transcriptase inhibitors, and protease inhibitors.
       The addition of these agents to the antiretroviral armamentarium will
       expand the treatment options available to clinicians who treat patients
       with HIV infection.
 DE    Antiviral Agents/*THERAPEUTIC USE  Dideoxynucleosides/THERAPEUTIC USE
       Human  HIV Infections/*DRUG THERAPY  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).